share_log

POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

POS AM：修改註冊聲明表
美股sec公告 ·  04/23 00:38
牛牛AI助理已提取核心訊息
180 Life Sciences Corp. has filed a post-effective amendment to a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The amendment relates to the registration of common stock shares that may be sold by a selling stockholder, Armistice Capital, LLC. The shares in question are issuable upon the exercise of previously issued warrants, including the July 2022 Common Warrants, December 2022 Common Warrants, April 2023 Common Warrants, and December 2023 Common Warrants. The selling stockholder may sell the shares through various methods such as block trades, private transactions, or on the open market. The filing also includes details on indemnification agreements, recent unregistered sales of securities, and the potential impact of the shares' sale on the company's control. The registration allows the selling stockholder to publicly sell their shares, but does not necessarily indicate that they will do so. The company will not receive any proceeds from the sale of shares by the selling stockholder.
180 Life Sciences Corp. has filed a post-effective amendment to a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The amendment relates to the registration of common stock shares that may be sold by a selling stockholder, Armistice Capital, LLC. The shares in question are issuable upon the exercise of previously issued warrants, including the July 2022 Common Warrants, December 2022 Common Warrants, April 2023 Common Warrants, and December 2023 Common Warrants. The selling stockholder may sell the shares through various methods such as block trades, private transactions, or on the open market. The filing also includes details on indemnification agreements, recent unregistered sales of securities, and the potential impact of the shares' sale on the company's control. The registration allows the selling stockholder to publicly sell their shares, but does not necessarily indicate that they will do so. The company will not receive any proceeds from the sale of shares by the selling stockholder.
180 生命科學公司已於 2024 年 4 月 19 日向美國證券交易委員會 (SEC) 提交了對 S-1 表格註冊聲明的生效後修正案。該修正案涉及出售股東Armistice Capital, LLC可以出售的普通股的註冊。有關股票可在行使先前發行的認股權證後發行，包括2022年7月的普通認股權證、2022年12月的普通認股權證、2023年4月的普通認股權證和2023年12月的普通認股權證。賣出股東可以通過各種方式出售股票，例如大宗交易，私人交易或公開市場。該文件還包括有關賠償協議、最近未註冊證券銷售以及股票出售對公司控制權的潛在影響的詳細信息。註冊允許出售股東公開出售其股票，但不一定表示他們會這樣做。該公司不會從出售股票的股東獲得任何收益。
180 生命科學公司已於 2024 年 4 月 19 日向美國證券交易委員會 (SEC) 提交了對 S-1 表格註冊聲明的生效後修正案。該修正案涉及出售股東Armistice Capital, LLC可以出售的普通股的註冊。有關股票可在行使先前發行的認股權證後發行，包括2022年7月的普通認股權證、2022年12月的普通認股權證、2023年4月的普通認股權證和2023年12月的普通認股權證。賣出股東可以通過各種方式出售股票，例如大宗交易，私人交易或公開市場。該文件還包括有關賠償協議、最近未註冊證券銷售以及股票出售對公司控制權的潛在影響的詳細信息。註冊允許出售股東公開出售其股票，但不一定表示他們會這樣做。該公司不會從出售股票的股東獲得任何收益。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。